Behavioural self-assessment tool can encourage medicines adherence

The ‘Social, Psychological, Usage and Rational’ tool measures the medicines non-adherence risk of patients by analysing social, psychological, usage and rational drivers.
An older man reads the contents on a bottle of medicine

Patients’ risk of not adhering to medication plans can be predicted by the ‘Social, Psychological, Usage and Rational’ (SPUR) tool, which can also help understand social and psychological factors behind non-adherence, leading to more personalised interventions, according to a study.

In the study, published in Nature Scientific Reports on 26 September 2025, researchers retrospectively examined 1,800 patients with chronic conditions, over four years across three countries: the UK, US and France — more than half of which had type 2 diabetes mellitus (T2DM).

Researchers used the SPUR tool, which measures non-adherence risk by looking at the drivers behind non-adherence and places those drivers into four categories: social, psychological, usage and rational.

In this study, researchers used a SPUR 6/24 model, which features six initial questions followed by a further 24 questions. Researchers analysed the reasons why people with long-term illness may not take their medicine as directed. 

Study authors said that while people often cite rational reasons, such as simply forgetting or the cost or perceived lack of effectiveness of the medicine, there are very often deeper reasons, such as a patient’s feelings about how their illness and its treatment affect their social interactions, or how they feel their illness influences their role in society.

Support for non-adherent patients may not be effective if there is a deeper, underlying reason behind the patient’s reluctance — especially if those reasons are more related to social or psychological factors, the authors said.

However, the authors noted that a potential limitation of the study was a high representation of people with T2DM, which could have led to an overrepresentation of the behavioural, psychological and social dynamics specific to this condition.

“Diabetes, particularly T2DM, is well-documented to involve a complex interplay of psychological constructs, such as identity conflict, health-related distress and social stigma, which may accentuate the role of psychological and social factors in adherence behaviour,” they said.

In a press release published on 4 November 2025, study author Joshua Wells, honorary lecturer at Kingston University, commented: “The study has not only demonstrated the predictive value of SPUR to identify non-adherence risk but also identified a novel framework for behaviour in terms of the interaction of drivers behind non-adherence, which had not previously been described.

“By identifying these deeper layers, providers can choose more targeted behavioural change techniques and a more holistic approach that addresses the patient’s discomfort stemming from an interplay of psychological, social and other factors, reducing non-adherence risk in those living with chronic conditions.”

Read more: How do we solve a problem like medicines adherence?

Last updated
Citation
The Pharmaceutical Journal, PJ November 2025, Vol 316, No 8003;316(8003)::DOI:10.1211/PJ.2025.1.385554

    Please leave a comment 

    You may also be interested in